Anzeige
Mehr »
Login
Donnerstag, 20.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Warum diese Aktie jetzt massiv durchstartet und wie Sie zu neuen Gratis-Aktien kommen…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRU | ISIN: US30233G2093 | Ticker-Symbol: PV3B
Tradegate
19.06.24
08:42 Uhr
8,232 Euro
+0,128
+1,58 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
EYEPOINT PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EYEPOINT PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,8068,14216:57
7,8068,14216:57

Aktuelle News zur EYEPOINT PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals to Host R&D Day on June 26, 20241
MoEyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)681WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
05.06.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference3
28.05.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report2
16.05.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)225WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
09.05.EyePoint Pharmaceuticals, Inc. - 10-Q, Quarterly Report7
07.05.Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)6
06.05.Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge10
06.05.EyePoint reports midstage trial fail for Duravyu, raising serious questions about the prospect11
06.05.EyePoint Stock Plunges 34% As Eye Treatment Fails To Meet Trial Goal14
06.05.NanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare movers6
06.05.EyePoint tumbles 30% premarket on failed Phase 2 study8
06.05.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report5
06.05.Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?8
06.05.HotStocks USA: -29 % bei EYEPOINT PHARMACEUTICALS3
06.05.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy313- DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months - - DURAVYU continues to demonstrate favorable safety and tolerability profile with...
► Artikel lesen
18.04.Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers40
16.04.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)111WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
► Artikel lesen
02.04.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists7
18.03.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)162WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
► Artikel lesen
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1